Newton H B, Scott S R, Volpi C
Division of Neuro-Oncology, Dardinger Neuro-Oncology Center, Department of Neurology, Ohio State University Medical Center, Columbus, Ohio 43210, USA.
Br J Neurosurg. 2004 Oct;18(5):495-9. doi: 10.1080/02688690400012392.
Meningiomas account for 18-20% of all intracranial tumours and often recur despite surgical resection. Hydroxyurea is under evaluation as adjuvant therapy of meningiomas. In the authors' initial report of 17 patients with meningioma, hydroxyurea demonstrated modest efficacy, with a median time to progression (TTP) of 80 weeks. In the current study, 21 patients with meningioma have been placed on hydroxyurea (20 mg/kg/day orally), with extended follow-up of the original cohort. Eighteen of 20 evaluable patients (90%) responded with stable disease ranging from 20 to 328 + weeks (median TTP 176 weeks; 11 patients censored). Five of the stabilized patients progressed after 20, 56, 36, 216 and 56 weeks, respectively. Two patients had progressive disease after 10 weeks. Toxicity was mainly haematological. Hydroxyurea has modest activity against meningiomas and should be considered for patients who are poor surgical candidates, have unresectable or large residual meningiomas, or have progressed after surgical resection or irradiation, or both.
脑膜瘤占所有颅内肿瘤的18 - 20%，尽管进行了手术切除，仍常复发。羟基脲正在作为脑膜瘤的辅助治疗进行评估。在作者最初对17例脑膜瘤患者的报告中，羟基脲显示出一定疗效，中位进展时间（TTP）为80周。在当前研究中，21例脑膜瘤患者接受了羟基脲治疗（口服20 mg/kg/天），并对原队列进行了延长随访。20例可评估患者中有18例（90%）病情稳定，稳定时间为20至328 +周（中位TTP 176周；11例失访）。5例病情稳定的患者分别在20、56、36、216和56周后病情进展。2例患者在10周后病情进展。毒性主要为血液学毒性。羟基脲对脑膜瘤有一定活性，对于手术候选不佳、有不可切除或巨大残留脑膜瘤、或在手术切除或放疗后病情进展或两者皆有的患者，应考虑使用。
